DCT and melanoma: Here, in addition, we describe a novel activity of the HSP90 inhibitor 17-AAG which induces melanization in BRAFWT melanoma cells in a tyrosinase-independent manner while increasing expression of accessory melanogenic enzymes and tumor antigens [28, 29] TYRP1 and DCT.